Seoul [South Korea], October 11 (ANI): Samsung Biologics Co is accelerating its expansion in Japan, the world's third-largest pharmaceutical market. The South Korean company has signed contracts with half of Japan's top 10 pharmaceutical and biotech companies, rapidly strengthening its presence in the region, according to a report by Pulse, the English service of Maeil Business Newspaper Korea.

"We have signed contracts with four of Japan's top 10 pharma companies and are in final talks with one more," the report quoted Samsung Biologics CEO John Rim at BioJapan 2025 held in Yokohama on Thursday.

"BioJapan is a crucial event for us. To expand our client base from the global top 20 to the top 40 pharmaceutical companies, collaboration with Japanese firms is essential. That's why we establ

See Full Page